5 AI-Powered Risk Adjustment Solutions for Payers and Providers
Commercial disclosure: RAAPID is the client product featured in this guest post.
An AI-suggested hierarchical condition category (HCC) code should be traceable to supporting chart evidence.
We compared five options for that review task and the workflows around it, using desk research rather than hands-on testing.
Key Takeaways
- RAAPID is our top pick for evidence-first review and flexible delivery.
- Datavant combines chart retrieval, coding, and quality review.
- Cotiviti covers prospective, concurrent, and retrospective work with operational services.
- Innovaccer connects risk workflows with clinical data and electronic health records (EHRs).
- Reveleer links code suggestions to evidence and requires coder confirmation.
How we picked
We reviewed vendor documentation, vendor-published customer evidence, and category-specific KLAS findings. Product pages were checked October 9, 2026.
We compared evidence visibility, human review, prospective and retrospective coverage, integration, delivery choices, service scope, and pricing transparency.
These are workflow-fit judgments, not measured performance rankings. Several alternatives also offer traceability and prospective workflows; we do not treat those features as exclusive to our top pick.
RAAPID
RAAPID pros
- HCC suggestions linked to MEAT (monitor, evaluate, assess, treat) chart evidence.
- Pre-visit gap identification, evidence filtering, and post-visit documentation review.
- EHR-oriented alerts for prospective review.
- Risk Adjustment Data Validation (RADV) audit console with visibility and alerts.
- Managed coding, in-house coding on the platform, or AI as a Service via API.
RAAPID cons
- No verified public price schedule.
- Confirm named-EHR connector scope.
Why we picked RAAPID
We rank RAAPID first for evidence-first review and delivery flexibility. We would shortlist RAAPID’s risk adjustment solution when the priority is reviewing HCC suggestions alongside their supporting chart evidence.
We value the in-house, managed, and API options; each still calls for clinical judgment during review. Pre-visit filtering and post-visit review also make it worth considering beyond retrospective coding.
RAAPID reports 100% would repurchase in the May 2026 KLAS Emerging Company Spotlight, marked Emerging Data, n=5, a vendor-hosted summary of five interviews rather than a broad endorsement or an award.
RAAPID pricing
Public pricing was not listed on the reviewed pages; request a scoped quote that separates software, integration, and coding services so you compare the work included rather than a headline figure.
Datavant
Datavant pros
- Digital and traditional record acquisition.
- Natural language processing assists coding and compares codes with prior results.
- Quality review, analytics, and searchable chart access.
Datavant cons
- Data formats and reporting frequency require project scoping.
- No public monthly price verified.
Why we picked Datavant
We place Datavant second for retrieval-centered programs. Its platform connects chart prioritization, acquisition, coding, and quality review. Datavant advertises 42M charts coded annually, a vendor-reported scale figure, not a quality benchmark.
Datavant was a 2026 Best in KLAS winner for Risk Adjustment: Coding, Retrieval & Compliance Solutions.
Datavant pricing
Public pricing was not listed on the reviewed pages; request a scoped quote. Separate retrieval, coding, quality review, and platform access rather than assuming one fee covers everything.
Cotiviti
Cotiviti pros
- Prospective, concurrent, and retrospective coverage.
- Natural language processing supports coding with expert oversight.
- Second-level review addresses unsupported conditions and additional coding opportunities.
Cotiviti cons
- Buyers must scope which modules and services apply to their program.
- No public monthly price verified.
Why we picked Cotiviti
We picked Cotiviti for buyers seeking software and operational services across all three review stages. Its April 16, 2026 announcement described a provider portfolio combining its services with Edifecs technology.
Cotiviti’s About page reports more than 200 payer and health system clients, a company-wide count rather than a risk-adjustment-only customer count. We would define staffing responsibilities alongside the technology scope.
Cotiviti pricing
Public pricing was not listed on the reviewed pages; request a scoped quote. Ask for module- and service-specific costs.
Innovaccer
Innovaccer pros
- Direct write-back to electronic records for risk-adjustment documentation.
- Predictive suspecting flags members with potentially unreported or miscoded conditions.
- Linked chart retrieval, coding validation, prioritized review lists, and reporting.
Innovaccer cons
- Confirm provider or payer package fit and local write-back configuration.
- No public monthly price verified.
Why we picked Innovaccer
We picked Innovaccer for teams connecting risk review to broader clinical data workflows.
Write-back depends on EHR integration, a core feature of modern healthcare software, so we would confirm it in the buyer’s configuration.
Suspected conditions remain candidates for review, not established diagnoses. Its platform was a 2026 Best in KLAS winner in Data Analytics Platform for Payers, awarded to its Galaxy risk adjustment and analytics platform, a separate category from risk-adjustment coding.
Innovaccer pricing
Public pricing was not listed on the reviewed pages; request a scoped quote. Include the data platform, integration, and required risk workflows.
Reveleer
Reveleer pros
- Retrospective recommendations show supporting chart excerpts and pages.
- Prospective workflows with named Epic and athenahealth integration support.
- Self-service, collaborative, or full-service delivery.
Reveleer cons
- EVE is embedded AI, not a separately purchasable application.
- A coder confirms every code, so staff the review step accordingly.
Why we picked Reveleer
We picked Reveleer for its explicit coder-confirmation step and evidence-linked recommendations. Its service arrangements support programs run by internal staff, with collaborative or full-service options.
The vendor cites 1.2M charts coded in 4 months in Reveleer’s vendor-published regional-health-plan case study, an undated, customer-specific result that should not become a delivery target for other buyers. We would confirm staffing and local integration requirements during scoping.
Reveleer pricing
Public pricing was not listed on the reviewed pages; request a scoped quote for the workflows and service level you need.
Conclusion
RAAPID is our top pick for evidence-first chart review and flexible delivery. Its documented evidence links and managed, in-house, and API options make it worth shortlisting without implying superiority on every criterion.
Include Datavant for retrieval-centered work or Cotiviti for service-supported programs. Before signing, ask shortlisted vendors to demonstrate an unsupported code using approved sample records, show the reviewer’s decision step, and separate software, integration, and service costs.
